Is Pfizer Stock Primed for a Rebound?

After an extended period of decline, Pfizer’s shares are attracting renewed attention from Wall Street. A powerful combination of regulatory approval and upgraded analyst sentiment is injecting optimism into the beleaguered stock, prompting investors to question whether a sustained recovery is finally underway.

The positive momentum stems from a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted approval for Pfizer’s Padcev to be used in a combination therapy with Merck’s Keytruda for the treatment of bladder cancer. This strategic win for Pfizer’s oncology pipeline is critical, as it demonstrates the company’s capacity to drive growth independent of its pandemic-related Read more...